eprex 2000 iu/ml injektioneste, liuos, esitäytetty ruisku
janssen-cilag oy - epoetinum alfa - injektioneste, liuos, esitäytetty ruisku - 2000 iu/ml - epoetiini
vafseo
akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemiset valmisteet - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.
recormon 1000 iu injektiokuiva-aine
orion oyj - epoetinum beta - injektiokuiva-aine - 1000 iu - epoetiini
recormon 2000 iu injektiokuiva-aine
orion oyj - epoetinum beta - injektiokuiva-aine - 2000 iu - epoetiini
recormon 5000 iu injektiokuiva-aine
orion oyj - epoetinum beta - injektiokuiva-aine - 5000 iu - epoetiini
recormon 10000 iu injektiokuiva-aine
orion oyj - epoetinum beta - injektiokuiva-aine - 10000 iu - epoetiini
retacrit 10000 iu/ml injektioneste, liuos, esitäytetty ruisku
abacus medicine a/s - epoetinum zeta - injektioneste, liuos, esitäytetty ruisku - 10000 iu/ml - epoetiini
reblozyl
bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - muut anemialääkkeet - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.
evrenzo
astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianemiset valmisteet - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).